Trump and Kennedy's health industry deals haven't been enforced and are at risk of vanishing

TL;DR

The Trump administration has focused on voluntary agreements with health industries to improve public health and lower costs.
These agreements, including those related to artificial dyes and prior authorization, often lack enforcement and transparent oversight.
Critics argue that these deals are more about political publicity than substantial, lasting change.
Initiatives like the removal of artificial dyes from food have faced delays, with many companies not meeting promised deadlines.
Insurance companies' pledges to reduce prior authorization have also fallen short, with limited progress and no public dashboards to track compliance.
Republicans view this approach as a winning strategy that aligns with their anti-regulatory stance and allows them to tout accomplishments.
The effectiveness of these voluntary deals is questioned, with concerns that they may unravel once political attention fades.
The administration's drug pricing agreements, termed 'most-favored-nation,' also rely on voluntary arrangements with limited scope and unknown long-term impact.

Continue reading the original article